MDxHealth Surge: MVM Partners’ Buy & Insider Confidence Boost Diagnostics Outlook
MDxHealth sees bullish momentum: MVM Partners’ €0.45 stake plus exec option buys hint at a diagnostics turnaround focused on prostate‑cancer precision medicine.
4 minutes to read